ArticleTrials2023

Comparison of the pathological response to 2 or 4 cycles of neoadjuvant CAPOX in II/III rectal cancer patients with low/intermediate risks: study protocol for a prospective, non-inferior, randomized control trial (COPEC trial).

Yu Shen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.